QuidelOrtho (QDEL) Q1 2025: Tariff Headwind of $30–40M Fully Offset as Labs Drive 7% Growth
QuidelOrtho’s Q1 2025 saw core labs deliver 7% growth and margin expansion, as management tackled a $30–40 million tariff headwind with decisive mitigation actions. Cost savings and pricing offset macro pressure, while the company reaffirmed full-year guidance despite COVID test declines and ongoing donor screening wind-down. With labs and flu combo tests anchoring recurring revenue, operational discipline remains central to the 2025 outlook.
Summary
- Tariff Mitigation: Management neutralized $30–40 million in tariff headwinds through cost and supply chain actions.
- Core Labs Resilience: Labs and immunohematology drove recurring revenue growth, offsetting COVID and donor screening declines.
- Margin Expansion Focus: Cost discipline and procurement initiatives are set to further expand margins through 2025.
Performance Analysis
QuidelOrtho’s Q1 2025 results demonstrated the company’s ability to deliver on its refocused strategy, with mid-single-digit revenue growth (6%) excluding COVID and donor screening. The labs business, comprising 54% of total revenue, grew 7% on the back of clinical chemistry and immunoassay demand, while immunohematology posted steady 4% growth. Point of care, at 25% of revenue, saw 8% growth (excluding COVID), with a strong flu season driving combo test demand and partially offsetting a 53% decline in COVID testing revenue.
Gross margin expanded 260 basis points year-over-year to 50.1%, attributable to higher-margin product mix and cost containment. Adjusted EBITDA margin rose 450 basis points to 23%, reflecting the impact of $18 million in operating expense reductions. Notably, adjusted diluted EPS surged 68% year-over-year, underscoring the earnings leverage from both revenue mix and cost actions. Regional performance was led by Japan, Asia-Pac, and Latin America, up 12% overall, while North America and EMEA posted underlying growth after adjusting for COVID and donor screening headwinds.
- Recurring Revenue Model Strength: Over 90% of sales are consumables, supporting predictability and margin stability.
- COVID Drag and Donor Screening Wind-Down: COVID revenue fell sharply, and donor screening contracted 62%, but these were anticipated and offset by core growth.
- Cash Flow and Leverage: Adjusted free cash flow conversion was 29% of EBITDA, with net debt to EBITDA improving to 4.2x, reflecting capital allocation discipline.
Management’s cost savings and procurement-driven initiatives are on track to deliver an additional $30–50 million in 2025, on top of the $100 million annualized savings plan. This underpins both margin expansion and the ability to neutralize macro headwinds, including tariffs.
Executive Commentary
"Our business is based on a recurring revenue model with more than 90% of our sales coming from consumables and a small percentage coming from instrument placements. The majority of our manufacturing is based in the United States, and over the past three years, we have invested nearly a billion dollars in US-based manufacturing and R&D."
Brian Blazer, President and Chief Executive Officer
"Adjusted EBITDA was 160 million compared to 132 million in the prior year period. Adjusted EBITDA margin was 23%, a 450 basis point improvement, which again reflects the cost savings actions we have taken."
Joe Buskey, Chief Financial Officer
Strategic Positioning
1. Tariff Response and Global Footprint
QuidelOrtho faced a $30–40 million tariff impact in 2025, primarily from UK-manufactured immunoassays shipped to the US and a small subset of China shipments. The company’s global manufacturing footprint—spanning the US, UK, China, Europe, and Mexico—enabled rapid supply chain shifts, supplier changes, and inventory repositioning. Selective pricing actions and cost controls provided additional mitigation, allowing management to maintain guidance.
2. Recurring Consumables Revenue Model
Over 90% of revenue is generated from consumables, which are reagents and test kits used repeatedly on installed instruments. This model supports revenue predictability, customer stickiness, and margin resilience, especially as instrument placements are a minor share of sales. Long contracts and loyal customers in labs and immunohematology reinforce visibility.
3. Margin Expansion Through Procurement and Cost Discipline
Cost savings remain central to the margin narrative. After headcount reductions in 2024, QuidelOrtho is now targeting direct and indirect procurement, inventory utilization, and capital expense management for incremental savings. The company expects to realize $50 million in cost savings in the first half and an additional $30–50 million through the year, supporting margin expansion and offsetting macro pressures.
4. Product Mix and Platform Strategy
Growth in flu combo and molecular diagnostics is offsetting COVID declines. The COVID-flu combo test has shown durable demand, while the Savannah respiratory panel is nearing FDA submission, aiming to capture a larger share of the fast-growing molecular diagnostics segment. Management’s focus on platform utility and content expansion underpins commercial execution and future growth.
5. Regional Diversification and China Strategy
International regions, notably Asia-Pac and EMEA, delivered double-digit labs growth, while China’s clinical chemistry and immunohematology businesses are expected to achieve mid to high single-digit growth for the full year. Management cited strong visibility, with triage softness and order timing as the only near-term drags.
Key Considerations
Q1 2025 highlighted QuidelOrtho’s ability to execute on cost savings and supply chain agility, while maintaining growth in core diagnostic segments and navigating macro headwinds.
Key Considerations:
- Tariff Impact Neutralization: Full mitigation of $30–40 million in tariff exposures through supply chain, cost, and pricing levers.
- Recurring Revenue Anchors: Consumables-driven model provides resilience against episodic declines in COVID and donor screening businesses.
- Margin Expansion Trajectory: Procurement and operational initiatives support ongoing EBITDA margin improvement, targeting mid to high 20% range in coming years.
- China Growth Visibility: Management expects mid to high single-digit growth in China, supported by labs and immunohematology, despite triage reimbursement headwinds.
- Pipeline Execution: Savannah respiratory panel submission is a key near-term milestone for molecular diagnostics expansion.
Risks
Tariff and macro volatility remain material risks, especially if trade policy shifts or exemptions lapse, potentially impacting cost structure or supply chain continuity. COVID testing demand is inherently unpredictable, and further declines could challenge top-line growth. Regulatory delays (notably FDA approval timelines for Savannah) and competitive responses in core lab and molecular diagnostics also warrant close monitoring. Management’s ability to sustain cost discipline and execute on procurement savings is central to margin targets.
Forward Outlook
For Q2 2025, QuidelOrtho guided to:
- Typical seasonality, with Q2 as the lowest revenue quarter and Q4 as the highest for both revenue and margins.
- China Q2 revenue softness due to shipment timing, to be offset in the second half.
For full-year 2025, management maintained guidance:
- Total reported revenue of $2.6–2.81 billion.
- Adjusted EBITDA of $575–615 million (22% margin).
- Adjusted diluted EPS of $2.07–2.57.
- COVID revenue of $110–149 million, with a potential summer spike.
- Free cash flow conversion of 25–30% of adjusted EBITDA, improving in the second half.
Management cited incremental cost savings, procurement initiatives, and recurring revenue strength as key drivers supporting the guidance and margin outlook.
- Tariff mitigation plans are expected to fully offset gross impacts.
- Savannah respiratory panel FDA submission remains a near-term focus.
Takeaways
QuidelOrtho’s Q1 2025 showcased disciplined execution, with recurring consumables revenue and margin expansion offsetting COVID and donor screening headwinds.
- Cost and Supply Chain Agility: Management’s ability to neutralize tariff impacts without guidance cuts demonstrates operational flexibility and strategic foresight.
- Recurring Revenue Model Validated: Labs and immunohematology growth reinforce the value of the consumables-driven business model, supporting margin and cash flow.
- Pipeline and Regional Diversification: The Savannah panel and international growth are critical watchpoints for sustained top-line momentum into 2026.
Conclusion
QuidelOrtho delivered a solid Q1 2025, with core labs and cost discipline driving profit and margin gains, while deftly managing macro and tariff headwinds. Recurring revenue, procurement-driven savings, and a robust product pipeline position the company for continued profitable growth.
Industry Read-Through
QuidelOrtho’s tariff mitigation approach and margin expansion underscore the critical value of supply chain agility and cost discipline for diagnostics peers facing similar macro and trade pressures. The recurring consumables model demonstrates resilience as COVID demand normalizes, while the focus on platform expansion and molecular diagnostics is a key read-through for competitors seeking to offset legacy test declines. International diversification and procurement optimization are likely to become more central across the diagnostics sector as global trade and reimbursement landscapes remain volatile. Investors should watch for similar cost and margin levers among other diagnostics and medtech players navigating a post-pandemic demand environment.